8-K 1 d744045d8k.htm FORM 8-K Form 8-K












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2019



Myovant Sciences Ltd.

(Exact name of registrant as specified in its charter)




Bermuda   001-37929   98-1343578

(State or other jurisdiction

of incorporation)



File No.)


(I.R.S. Employer

Identification No.)

Suite 1, 3rd Floor

11-12 St. James’s Square

London SW1Y 4LB

United Kingdom

  Not Applicable
(Address of principal executive office)   (Zip Code)

Registrant’s telephone number, including area code: +(441) 295-5950



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Shares, par value

$0.000017727 per share

  MYOV   New York Stock Exchange




Item 8.01.

Other Events.

On May 14, 2019, Myovant Sciences Ltd. made available a slide presentation regarding the top-line results for its LIBERTY 1 Phase 3 clinical trial evaluating once daily relugolix combination therapy in women with uterine fibroids. The slide presentation is attached hereto as Exhibit 99.1 and is incorporated by reference here.


Item 9.01.

Financial Statements and Exhibits.





99.1    Slide Presentation


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 14, 2019

    Myovant Sciences Ltd.

/s/ Frank Karbe

    Name:   Frank Karbe
    Title:   Principal Financial and Accounting Officer